Timber Creek Capital Management LLC boosted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 66.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,430 shares of the conglomerate's stock after purchasing an additional 10,189 shares during the quarter. Danaher comprises about 1.4% of Timber Creek Capital Management LLC's holdings, making the stock its 25th biggest position. Timber Creek Capital Management LLC's holdings in Danaher were worth $5,213,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of DHR. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Danaher by 575.0% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,728 shares of the conglomerate's stock valued at $355,000 after buying an additional 1,472 shares in the last quarter. IFM Investors Pty Ltd increased its holdings in Danaher by 11.1% during the first quarter. IFM Investors Pty Ltd now owns 147,142 shares of the conglomerate's stock worth $30,164,000 after buying an additional 14,734 shares during the last quarter. OneDigital Investment Advisors LLC increased its holdings in Danaher by 4.7% during the first quarter. OneDigital Investment Advisors LLC now owns 17,535 shares of the conglomerate's stock worth $3,595,000 after buying an additional 793 shares during the last quarter. 4J Wealth Management LLC increased its holdings in Danaher by 16.5% during the first quarter. 4J Wealth Management LLC now owns 1,354 shares of the conglomerate's stock worth $278,000 after buying an additional 192 shares during the last quarter. Finally, Spear Holdings RSC Ltd purchased a new position in shares of Danaher in the first quarter worth about $55,740,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Danaher
In other news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
DHR has been the subject of several recent analyst reports. TD Cowen boosted their price objective on shares of Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research note on Wednesday, April 23rd. UBS Group dropped their target price on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. JPMorgan Chase & Co. dropped their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Tuesday, April 22nd. The Goldman Sachs Group dropped their target price on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average price target of $248.61.
Get Our Latest Stock Report on DHR
Danaher Stock Performance
Shares of NYSE DHR traded up $0.58 during trading on Friday, hitting $203.08. The company had a trading volume of 1,390,744 shares, compared to its average volume of 3,501,434. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a 50 day simple moving average of $195.63 and a 200 day simple moving average of $207.38. The firm has a market capitalization of $145.33 billion, a P/E ratio of 39.43, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. As a group, analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.
Danaher Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. Danaher's dividend payout ratio (DPR) is 24.85%.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
